SCHEMBL1878739

SCHEMBL1878739

CC(c1ccccc1)N(Cc1cccc(CNCc2ccccn2)c1)Cc1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.50
KMT2A Q03164 6/20 0.50
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 3/20 0.44
L3MBTL1 Q9Y468 5/20 0.43
SMARCA2 P51531 1/20 0.42
CYP2D6 P10635 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP1A2 P05177 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
CCR5 P51681 1/20 0.39
TP53 P04637 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
RECQL P46063 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29823902 1.00 MEN1 (0.50) MEN1KMT2AALDH1A1KDM4EL3MBTL1
SCHEMBL1874025 0.81 ALDH1A1 (0.44) MEN1KMT2AALDH1A1KDM4EL3MBTL1
SCHEMBL1881875 0.79 ALDH1A1 (0.43) MEN1KMT2AALDH1A1KDM4EL3MBTL1
SCHEMBL30225577 0.78 KMT2A (0.68) MEN1KMT2AALDH1A1KDM4EL3MBTL1
SCHEMBL14931741 0.78 KMT2A (0.68) MEN1KMT2AALDH1A1KDM4EL3MBTL1
SCHEMBL14025550 0.76 ALDH1A1 (0.48) MEN1KMT2AALDH1A1KDM4EL3MBTL1
SCHEMBL4428290 0.75 ALDH1A1 (0.53) MEN1KMT2AALDH1A1KDM4EL3MBTL1
SCHEMBL1876917 0.74 HPGD (0.40) MEN1KMT2AALDH1A1KDM4EL3MBTL1
SCHEMBL1874483 0.72 CYP2D6 (0.39) MEN1KMT2AALDH1A1KDM4EL3MBTL1
SCHEMBL22305532 0.72 ALDH1A1 (0.60) MEN1KMT2AALDH1A1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371361-A1 Methods to mobilize progenitor/stem cells Genzyme Global S.à.r.l. (LU) 2011-10-05 EP claimed
US-7935692-B2 Methods to mobilize progenitor/stem cells GENZYME CORPORATION (US) 2011-05-03 US claimed
US-20100035941-A1 METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION GENZYME CORPORATION 2010-02-11 US claimed
US-20060264434-A1 Chemokine receptor binding heterocyclic compounds ANORMED INC. (CA) 2006-11-23 US claimed
EP-1163238-B1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2006-05-31 EP claimed
US-20040235823-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-25 US claimed
JP-2003524620-A 2003-08-19 JP claimed
EP-1163238-A1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2001-12-19 EP claimed
WO-2000056729-A1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2000-09-28 WO claimed
WO-2025230907-A1 A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-11-06 WO disclosed
US-20250295698-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS ENSOMA INC (US) 2025-09-25 US disclosed
US-20250032549-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS ENSOMA INC (US) 2025-01-30 US disclosed
US-20240285831-A1 METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION KEEFER, Edward (US) 2024-08-29 US disclosed
US-20240189387-A1 DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS ENSOMA, INC. 2024-06-13 US disclosed
US-6750348-B1 PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE ANORMED, INC. (CA) 2004-06-15 US disclosed
EP-1411918-A2 METHODS TO MOBILIZE PROGENITOR/STEM CELLS ANORMED INC. (CA) 2004-04-28 EP disclosed
US-20030130250-A1 Methods to mobilize progenitor/stem cells ANORMED, INC. (CA) 2003-07-10 US disclosed
WO-2003011277-A2 METHODS TO MOBILIZE PROGENITOR/STEM CELLS ANORMED INC. (CA) 2003-02-13 WO disclosed
EP-1163238-A1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2001-12-19 EP disclosed
WO-2000056729-A1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264434-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR4, CXCR1 MEN1 4013/4885KMT2A 4150/4885ALDH1A1 1458/4885
US-20240189387-A1 DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS CXCL12, MCL1, MYADM MEN1 70/4885KMT2A 1317/4885ALDH1A1 1130/4885
US-20100035941-A1 METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION CCR2, CXCR4, CXCR2 MEN1 4046/4885KMT2A 1732/4885ALDH1A1 784/4885
US-20250032549-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS CXCL12, CD44, CD47 MEN1 1187/4885KMT2A 1455/4885ALDH1A1 353/4885
US-20240285831-A1 METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION CXCR3, CXCL12, CXCR4 MEN1 4348/4885KMT2A 3729/4885ALDH1A1 2426/4885
US-20030130250-A1 Methods to mobilize progenitor/stem cells CXCR4, CXCL12, CXCR2 MEN1 3350/4885KMT2A 1274/4885ALDH1A1 301/4885
US-20250295698-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS CXCL12, CSF3R, THPO MEN1 185/4885KMT2A 1994/4885ALDH1A1 671/4885
US-20040235823-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR4, CXCR1 MEN1 4366/4885KMT2A 4002/4885ALDH1A1 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.